European Parliament
2014-2019

Plenary sitting

B8-0106/2017

11.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133

on fibrodysplasia ossificans progressiva

Mireille D'Ornano

B8-0106/2017

Motion for a European Parliament resolution on fibrodysplasia ossificans progressiva

The European Parliament,

– having regard to Article 168 TFEU,

– having regard to Rule 133 of its Rules of Procedure,

A. whereas fibrodysplasia ossificans progressiva (FOP) is a hereditary disease caused by a mutation in the ACVR1 gene which affects 1 in 2 million people worldwide and is characterised by the progressive heterotopic ossification of fibrous tissue, resulting in paralysis, and whereas sufferers have an average life expectancy of 40;

B. whereas treatments include corticosteroids and prophylactics which minimise the trauma responsible for the progressive bone growth typical of FOP;

C. whereas, on 19 November 2014, Palovarotene was granted Orphan Medicinal Product Designation by the European Medicines Agency during Phase 2 clinical trials and a similar designation by the United States Food and Drug Administration, which declared it subject to a simplified marketing authorisation procedure;

1. Encourages the Commission to support research into a cure for FOP and to facilitate the placing on the market of all FOP treatments, Palovarotene in particular, as and when required.